Af­ter hash­ing out come­back plans, De­ci­phera looks to raise $125M from stock sale

Ear­li­er in Jan­u­ary, De­ci­phera out­lined plans for a new Phase III study of its ty­ro­sine ki­nase in­hibitor Qin­lock, still hop­ing to move it in­to an ear­li­er line of treat­ment for di­ges­tive tract can­cer af­ter it failed a piv­otal tri­al in 2021.

But in or­der to run a new clin­i­cal tri­al, De­ci­phera needs cash. So the Waltham, MA biotech is sell­ing its shares via a pub­lic of­fer­ing, it an­nounced Wednes­day af­ter­noon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER